Skin Cancer

Clutter clearing speaker/author turned two-time cancer survivor shares her holiday tips.

According to a recent trial, an immunotherapy combination was shown to be effective in high-risk melanoma. But because of the high toxicity profile, more research is needed.

A six-year breast cancer survivor and three-year melanoma survivor reflects back and offers hope.

In an interview with CURE, James Allison, Ph.D. talks about the progress immunotherapy has made, as well as potential combinations with immunotherapy and other treatment types to provide better outcomes for patients.

Breast cancer and melanoma survivor finds herself waiting for results again.

CURE spoke with expert Jason Luke about updates and future prospects for immunotherapy in melanoma.

Do I want to be asked how I am doing? A six year breast cancer and three-year melanoma survivor ponders this question.

A two-time cancer survivor shares her experiences with cancer's side effects.

Yervoy reduced risk of death for patients with high-risk stage 3 melanoma in a recent study.

A new drug combination showed improved progression-free survival for patients with advanced melanoma, according to a recent study.

Cancer survivor rethinks her home for easier management after cancer.

Jedd D. Wolchok discusses the future of immunotherapy in melanoma treatment.

Because cancer is an invisible disease, most patients can keep it under wraps when out in public, but there are some instances when we need to play 'the cancer card.'

As a survivor of cancer, life has enough difficulty without daily painful reminders. Let go of items that create emotional clutter today.

CURE spoke with Yvonee Saenger about the future use of Opdivo and Yervoy in melanoma.

Breast cancer and melanoma survivor works on resilience to cope with her two cancers.

When a cancer diagnosis requires a lifestyle overhaul, it's important to recognize the gifts this forced transition brings.

The facts and figures of what the trajectory of a melanoma diagnosis looks like.

Virginia nurses raised awareness about skin cancer risk by evaluating people’s faces for sun damage.

While cancer may be a part of a survivor's identity, there are other aspects, too.

Yvonne Saenger, director of melanoma and immunotherapy at Columbia University Medical Center, discusses the side effects patients should look out for when they are on immunotherapy, and how to determine if they are experiencing normal therapy-induced fatigue or if they are suffering from a hormone reaction and should go see their medical team.